Alogliptin (Page 8 of 8)

PRINCIPAL DISPLAY PANEL — 6.25 mg Tablet Bottle Label

Rx Only

NDC 45802-087-65

Alogliptin
Tablets
6.25 mg

Dispense with
Medication Guide

30 Tablets Perrigo®

PRINCIPAL DISPLAY PANEL -- 6.25 mg Tablet Bottle Label
(click image for full-size original)

PRINCIPAL DISPLAY PANEL — 12.5 mg Tablet Bottle Label

Rx Only

NDC 45802-103-65

Alogliptin
Tablets
12.5 mg

Dispense with
Medication Guide

30 Tablets Perrigo®

PRINCIPAL DISPLAY PANEL -- 12.5 mg Tablet Bottle Label
(click image for full-size original)

PRINCIPAL DISPLAY PANEL — 25 mg Tablet Bottle Label

Rx Only

NDC 45802-150-65

Alogliptin
Tablets
25 mg

Dispense with
Medication Guide

30 Tablets Perrigo®

PRINCIPAL DISPLAY PANEL -- 25 mg Tablet Bottle Label
(click image for full-size original)
ALOGLIPTIN alogliptin tablet, film coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:45802-087
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Alogliptin Benzoate (Alogliptin) Alogliptin 6.25 mg
Inactive Ingredients
Ingredient Name Strength
Mannitol
HYDROXYPROPYL CELLULOSE (90000 WAMW)
Microcrystalline Cellulose
Croscarmellose sodium
Magnesium stearate
Hypromellose 2910 (6 MPA.S)
Titanium dioxide
Polyethylene Glycol 8000
Ferric oxide Red
Ferrosoferric oxide
Shellac
Butyl Alcohol
Alcohol
Product Characteristics
Color PINK (Light pink) Score no score
Shape OVAL (biconvex) Size 9mm
Flavor Imprint Code TAK;ALG;6;25
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:45802-087-65 30 TABLET, FILM COATED in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA authorized generic NDA022271 04/08/2016
ALOGLIPTIN alogliptin tablet, film coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:45802-103
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Alogliptin Benzoate (Alogliptin) Alogliptin 12.5 mg
Inactive Ingredients
Ingredient Name Strength
Mannitol
HYDROXYPROPYL CELLULOSE (90000 WAMW)
Microcrystalline Cellulose
Croscarmellose sodium
Magnesium stearate
Hypromellose 2910 (6 MPA.S)
Titanium dioxide
Polyethylene Glycol 8000
Ferric oxide Yellow
Ferrosoferric oxide
Shellac
Butyl Alcohol
Alcohol
Product Characteristics
Color YELLOW Score no score
Shape OVAL (biconvex) Size 9mm
Flavor Imprint Code TAK;ALG;12;5
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:45802-103-65 30 TABLET, FILM COATED in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA authorized generic NDA022271 04/08/2016
ALOGLIPTIN alogliptin tablet, film coated
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:45802-150
Route of Administration ORAL DEA Schedule
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
Alogliptin Benzoate (Alogliptin) Alogliptin 25 mg
Inactive Ingredients
Ingredient Name Strength
Mannitol
HYDROXYPROPYL CELLULOSE (90000 WAMW)
Microcrystalline Cellulose
Croscarmellose sodium
Magnesium stearate
Hypromellose 2910 (6 MPA.S)
Titanium dioxide
Polyethylene Glycol 8000
Ferric oxide Red
Ferrosoferric oxide
Shellac
Butyl Alcohol
Alcohol
Product Characteristics
Color RED (Light red) Score no score
Shape OVAL (biconvex) Size 9mm
Flavor Imprint Code TAK;ALG;25
Contains
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:45802-150-65 30 TABLET, FILM COATED in 1 BOTTLE None
Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
NDA authorized generic NDA022271 04/08/2016
Labeler — Perrigo New York Inc (078846912)

Revised: 07/2019 Perrigo New York Inc

All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.

This site is provided for educational and informational purposes only, in accordance with our Terms of Use, and is not intended as a substitute for the advice of a medical doctor, nurse, nurse practitioner or other qualified health professional.

Privacy Policy | Copyright © 2021. All Rights Reserved.